$GILD Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GILEAD SCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in GILEAD SCIENCES INC. Get notifications about new insider transactions in GILEAD SCIENCES INC for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 10 ... 46 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | A | 66.92 | 10,376 | 694,362 | 10,376 | |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | A | 0.00 | 2,241 | 0 | 2,241 | |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | A | 66.92 | 10,376 | 694,362 | 10,376 | |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | Kramer Kelly A. | Director | Option Exercise | A | 0.00 | 2,241 | 0 | 3,580 | |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | Kramer Kelly A. | Director | Option Exercise | A | 66.92 | 10,376 | 694,362 | 10,376 | |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | A | 0.00 | 2,241 | 0 | 5,611 | |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | A | 66.92 | 10,376 | 694,362 | 10,376 | |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 66.92 | 3,460 | 231,543 | 6,231 | 9.7 K to 6.2 K (-35.70 %) |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 0.00 | 6,810 | 0 | 9,691 | 2.9 K to 9.7 K (+236.38 %) |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | WOLD OLSEN PER | Director | Option Exercise | M | 0.00 | 1,787 | 0 | 0 | |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | WOLD OLSEN PER | Director | Buy | M | 0.00 | 1,787 | 0 | 93,330 | 91.5 K to 93.3 K (+1.95 %) |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | M | 0.00 | 1,787 | 0 | 0 | |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Buy | M | 0.00 | 1,787 | 0 | 122,258 | 120.5 K to 122.3 K (+1.48 %) |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | MADIGAN JOHN W | Director | Option Exercise | M | 0.00 | 1,787 | 0 | 0 | |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | MADIGAN JOHN W | Director | Buy | M | 0.00 | 1,787 | 0 | 18,548 | 16.8 K to 18.5 K (+10.66 %) |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | M | 0.00 | 1,787 | 0 | 3,370 | |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Buy | M | 0.00 | 1,787 | 0 | 30,124 | 28.3 K to 30.1 K (+6.31 %) |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 20.71 | 15,000 | 310,575 | 0 | |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 0.00 | 1,787 | 0 | 0 | |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 67.25 | 9,943 | 668,667 | 52,619 | 62.6 K to 52.6 K (-15.89 %) |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 20.71 | 15,000 | 310,575 | 62,562 | 47.6 K to 62.6 K (+31.54 %) |
| May 11 2017 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 0.00 | 1,787 | 0 | 47,562 | 45.8 K to 47.6 K (+3.90 %) |
| May 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 21.58 | 73,333 | 1,582,159 | 513,331 | |
| May 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 68.31 | 73,333 | 5,009,429 | 3,126,636 | 3.2 M to 3.1 M (-2.29 %) |
| May 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 21.58 | 73,333 | 1,582,159 | 3,199,969 | 3.1 M to 3.2 M (+2.35 %) |
| May 03 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Sell | S | 68.31 | 5,000 | 341,529 | 112,988 | 118 K to 113 K (-4.24 %) |
| Apr 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 21.58 | 73,333 | 1,582,159 | 586,664 | |
| Apr 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 67.85 | 10,500 | 712,385 | 3,126,636 | 3.1 M to 3.1 M (-0.33 %) |
| Apr 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 67.07 | 62,833 | 4,213,901 | 3,137,136 | 3.2 M to 3.1 M (-1.96 %) |
| Apr 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 21.58 | 73,333 | 1,582,159 | 3,199,969 | 3.1 M to 3.2 M (+2.35 %) |
| Apr 03 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Sell | S | 67.48 | 5,000 | 337,392 | 117,988 | 123 K to 118 K (-4.07 %) |
| Apr 03 2017 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | A | 0.00 | 146 | 0 | 19,149 | |
| Apr 03 2017 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Option Exercise | A | 0.00 | 197 | 0 | 25,838 | |
| Apr 03 2017 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | A | 0.00 | 49 | 0 | 6,359 | |
| Mar 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 21.58 | 73,333 | 1,582,159 | 659,997 | |
| Mar 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 70.38 | 73,333 | 5,161,206 | 3,126,636 | 3.2 M to 3.1 M (-2.29 %) |
| Mar 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 21.58 | 73,333 | 1,582,159 | 3,199,969 | 3.1 M to 3.2 M (+2.35 %) |
| Mar 02 2017 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Gift | G | 0.00 | 11,804 | 0 | 121,547 | 109.7 K to 121.5 K (+10.76 %) |
| Mar 02 2017 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Gift | G | 0.00 | 11,804 | 0 | 9,602 | 21.4 K to 9.6 K (-55.14 %) |
| Mar 02 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Gift | G | 0.00 | 1,430 | 0 | 122,988 | 124.4 K to 123 K (-1.15 %) |
| Feb 27 2017 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | M | 20.71 | 33,350 | 690,512 | 0 | |
| Feb 27 2017 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Sell | S | 69.30 | 20,365 | 1,411,374 | 120,471 | 140.8 K to 120.5 K (-14.46 %) |
| Feb 27 2017 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Buy | M | 20.71 | 33,350 | 690,512 | 140,836 | 107.5 K to 140.8 K (+31.03 %) |
| Feb 27 2017 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Option Exercise | M | 21.58 | 100,000 | 2,157,500 | 220,000 | |
| Feb 27 2017 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Buy | M | 21.58 | 100,000 | 2,157,500 | 1,165,924 | 1.1 M to 1.2 M (+9.38 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Payment of Exercise | F | 70.31 | 7,814 | 549,402 | 21,406 | 29.2 K to 21.4 K (-26.74 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 3,185 | 0 | 29,220 | 26 K to 29.2 K (+12.23 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 4,516 | 0 | 26,035 | 21.5 K to 26 K (+20.99 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 59.33 | 315 | 18,689 | 21,519 | 21.2 K to 21.5 K (+1.49 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Payment of Exercise | F | 70.31 | 8,389 | 589,831 | 1,065,924 | 1.1 M to 1.1 M (-0.78 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Grant | A | 0.00 | 3,429 | 0 | 1,074,313 | 1.1 M to 1.1 M (+0.32 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Grant | A | 0.00 | 11,606 | 0 | 1,070,884 | 1.1 M to 1.1 M (+1.10 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Grant | A | 59.33 | 315 | 18,689 | 1,059,278 | 1.1 M to 1.1 M (+0.03 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Gift | G | 0.00 | 4,354 | 0 | 125,505 | 121.2 K to 125.5 K (+3.59 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Gift | G | 0.00 | 4,354 | 0 | 2,715 | 7.1 K to 2.7 K (-61.59 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Payment of Exercise | F | 70.31 | 2,053 | 144,346 | 7,069 | 9.1 K to 7.1 K (-22.51 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Grant | A | 0.00 | 1,022 | 0 | 9,122 | 8.1 K to 9.1 K (+12.62 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Grant | A | 0.00 | 1,161 | 0 | 8,100 | 6.9 K to 8.1 K (+16.73 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Grant | A | 59.33 | 213 | 12,637 | 6,939 | 6.7 K to 6.9 K (+3.17 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | A | 70.31 | 123,210 | 8,662,895 | 123,210 | |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Payment of Exercise | F | 70.31 | 25,271 | 1,776,804 | 3,126,636 | 3.2 M to 3.1 M (-0.80 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Grant | A | 0.00 | 8,572 | 0 | 3,151,907 | 3.1 M to 3.2 M (+0.27 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Grant | A | 0.00 | 11,924 | 0 | 3,143,335 | 3.1 M to 3.1 M (+0.38 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Grant | A | 59.33 | 315 | 18,689 | 3,131,411 | 3.1 M to 3.1 M (+0.01 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Gift | G | 0.00 | 11,558 | 0 | 2,318,407 | 2.3 M to 2.3 M (+0.50 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Gift | G | 0.00 | 11,558 | 0 | 12,453 | 24 K to 12.5 K (-48.14 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Payment of Exercise | F | 70.31 | 7,070 | 497,092 | 24,011 | 31.1 K to 24 K (-22.75 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 3,021 | 0 | 31,081 | 28.1 K to 31.1 K (+10.77 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 5,773 | 0 | 28,060 | 22.3 K to 28.1 K (+25.90 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 59.33 | 315 | 18,689 | 22,287 | 22 K to 22.3 K (+1.43 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Payment of Exercise | F | 70.31 | 6,577 | 462,429 | 124,418 | 131 K to 124.4 K (-5.02 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Grant | A | 0.00 | 2,776 | 0 | 130,995 | 128.2 K to 131 K (+2.17 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Grant | A | 0.00 | 4,940 | 0 | 128,219 | 123.3 K to 128.2 K (+4.01 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Grant | A | 59.33 | 315 | 18,689 | 123,279 | 123 K to 123.3 K (+0.26 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 59.33 | 315 | 18,689 | 2,881 | 2.6 K to 2.9 K (+12.28 %) |
| Feb 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | M | 0.00 | 908 | 0 | 5,622 | |
| Feb 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 66.36 | 317 | 21,036 | 2,566 | 2.9 K to 2.6 K (-11.00 %) |
| Feb 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Buy | M | 0.00 | 908 | 0 | 2,883 | 2 K to 2.9 K (+45.97 %) |
| Feb 06 2017 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Option Exercise | A | 72.25 | 90,430 | 6,533,568 | 90,430 | |
| Feb 06 2017 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Option Exercise | A | 72.25 | 325,000 | 23,481,250 | 325,000 | |
| Feb 06 2017 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | A | 72.25 | 101,740 | 7,350,715 | 101,740 | |
| Feb 06 2017 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Option Exercise | A | 72.25 | 42,390 | 3,062,678 | 42,390 | |
| Feb 06 2017 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | A | 72.25 | 104,570 | 7,555,183 | 104,570 | |
| Feb 06 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | A | 72.25 | 115,870 | 8,371,608 | 115,870 | |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | M | 0.00 | 620 | 0 | 6,530 | |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 72.82 | 215 | 15,656 | 1,975 | 2.2 K to 2 K (-9.82 %) |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Buy | M | 0.00 | 620 | 0 | 2,190 | 1.6 K to 2.2 K (+39.49 %) |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 21.58 | 73,333 | 1,582,159 | 733,330 | |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 72.57 | 73,333 | 5,322,069 | 3,131,096 | 3.2 M to 3.1 M (-2.29 %) |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 21.58 | 73,333 | 1,582,159 | 3,204,429 | 3.1 M to 3.2 M (+2.34 %) |
| Jan 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 21.58 | 73,337 | 1,582,246 | 806,663 | |
| Jan 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 73.84 | 50,760 | 3,748,017 | 3,131,096 | 3.2 M to 3.1 M (-1.60 %) |
| Jan 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 73.04 | 22,577 | 1,648,954 | 3,181,856 | 3.2 M to 3.2 M (-0.70 %) |
| Jan 05 2017 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 21.58 | 73,337 | 1,582,246 | 3,204,433 | 3.1 M to 3.2 M (+2.34 %) |
| Jan 03 2017 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | A | 0.00 | 123 | 0 | 19,003 | |
| Jan 03 2017 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Option Exercise | A | 0.00 | 167 | 0 | 25,813 | |
| Jan 03 2017 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | A | 0.00 | 41 | 0 | 6,310 | |
| Dec 13 2016 | GILD | GILEAD SCIENCES IN ... | Meyers James R | EVP Worldwide Comme ... | Option Exercise | A | 72.70 | 28,040 | 2,038,508 | 28,040 | |
| Dec 05 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | M | 0.00 | 2,150 | 0 | 0 | |
| Dec 05 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Buy | M | 0.00 | 2,147 | 0 | 107,486 | 105.3 K to 107.5 K (+2.04 %) |
| Dec 05 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 0 | |
| Dec 05 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 73.33 | 100,000 | 7,332,870 | 3,131,096 | 3.2 M to 3.1 M (-3.09 %) |
| Dec 05 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 16.40 | 100,000 | 1,639,500 | 3,231,096 | 3.1 M to 3.2 M (+3.19 %) |
| Nov 29 2016 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Gift | G | 0.00 | 3,406 | 0 | 11,882 | 15.3 K to 11.9 K (-22.28 %) |
| Nov 29 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Gift | G | 0.00 | 10,000 | 0 | 2,306,849 | 2.3 M to 2.3 M (-0.43 %) |
| Nov 22 2016 | GILD | GILEAD SCIENCES IN ... | MADIGAN JOHN W | Director | Option Exercise | M | 20.71 | 105,000 | 2,174,025 | 0 | |
| Nov 22 2016 | GILD | GILEAD SCIENCES IN ... | MADIGAN JOHN W | Director | Sell | S | 74.86 | 105,000 | 7,860,059 | 16,761 | 121.8 K to 16.8 K (-86.23 %) |
| Nov 22 2016 | GILD | GILEAD SCIENCES IN ... | MADIGAN JOHN W | Director | Buy | M | 20.71 | 105,000 | 2,174,025 | 121,761 | 16.8 K to 121.8 K (+626.45 %) |
| Nov 14 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Sell | S | 79.00 | 10,000 | 790,000 | 122,964 | 133 K to 123 K (-7.52 %) |
| Nov 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 100,000 | |
| Nov 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 74.15 | 6,400 | 474,591 | 3,131,096 | 3.1 M to 3.1 M (-0.20 %) |
| Nov 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 73.73 | 93,600 | 6,901,456 | 3,137,496 | 3.2 M to 3.1 M (-2.90 %) |
| Nov 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 16.40 | 100,000 | 1,639,500 | 3,231,096 | 3.1 M to 3.2 M (+3.19 %) |
| Oct 05 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 200,000 | |
| Oct 05 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 78.57 | 500 | 39,283 | 3,131,096 | 3.1 M to 3.1 M (-0.02 %) |
| Oct 05 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 77.62 | 99,500 | 7,723,678 | 3,131,596 | 3.2 M to 3.1 M (-3.08 %) |
| Oct 05 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 16.40 | 100,000 | 1,639,500 | 3,231,096 | 3.1 M to 3.2 M (+3.19 %) |
| Oct 03 2016 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | A | 0.00 | 113 | 0 | 18,880 | |
| Oct 03 2016 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Option Exercise | A | 0.00 | 154 | 0 | 25,646 | |
| Oct 03 2016 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | A | 0.00 | 38 | 0 | 6,269 | |
| Oct 03 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | A | 0.00 | 13 | 0 | 2,150 | |
| Sep 26 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP Comm&Acs ALA, C ... | Sell | S | 81.84 | 5,000 | 409,220 | 132,964 | 138 K to 133 K (-3.62 %) |
| Sep 08 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Option Exercise | M | 20.74 | 70,000 | 1,451,800 | 0 | |
| Sep 08 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Sell | S | 77.74 | 70,000 | 5,442,080 | 1,058,963 | 1.1 M to 1.1 M (-6.20 %) |
| Sep 08 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Buy | M | 20.74 | 70,000 | 1,451,800 | 1,128,963 | 1.1 M to 1.1 M (+6.61 %) |
| Sep 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 300,000 | |
| Sep 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 78.19 | 4,400 | 344,047 | 3,131,096 | 3.1 M to 3.1 M (-0.14 %) |
| Sep 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Sell | S | 77.45 | 95,600 | 7,404,316 | 3,135,496 | 3.2 M to 3.1 M (-2.96 %) |
| Sep 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | M | 16.40 | 100,000 | 1,639,500 | 3,231,096 | 3.1 M to 3.2 M (+3.19 %) |
| Sep 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Gift | G | 0.00 | 156,714 | 0 | 3,131,096 | 3.3 M to 3.1 M (-4.77 %) |
| Sep 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Gift | G | 0.00 | 731,917 | 0 | 3,287,810 | 4 M to 3.3 M (-18.21 %) |
| Sep 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Buy | J | 0.00 | 731,917 | 0 | 731,917 | 0 to 731.9 K |
| Aug 31 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Gift | G | 0.00 | 3,225 | 0 | 109,743 | 113 K to 109.7 K (-2.85 %) |
| Aug 26 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Gift | G | 0.00 | 2,800 | 0 | 2,316,849 | 2.3 M to 2.3 M (-0.12 %) |
| Aug 25 2016 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Sell | S | 81.97 | 3,500 | 286,899 | 0 | 3.5 K to 0 (-100.00 %) |
| Aug 25 2016 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Grant | A | 0.00 | 3,500 | 0 | 3,500 | 0 to 3.5 K |
| Aug 23 2016 | GILD | GILEAD SCIENCES IN ... | Kramer Kelly A. | Director | Option Exercise | A | 0.00 | 1,339 | 0 | 1,339 | |
| Aug 23 2016 | GILD | GILEAD SCIENCES IN ... | Kramer Kelly A. | Director | Option Exercise | A | 81.00 | 5,611 | 454,491 | 5,611 | |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Option Exercise | M | 20.74 | 70,000 | 1,451,800 | 70,000 | |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Option Exercise | M | 20.74 | 70,000 | 1,451,800 | 70,000 | |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Option Exercise | M | 20.74 | 70,000 | 1,451,800 | 70,000 | |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Sell | S | 70.94 | 70,000 | 4,965,590 | 1,058,963 | 1.1 M to 1.1 M (-6.20 %) |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Sell | S | 70.94 | 70,000 | 4,965,590 | 1,058,963 | 1.1 M to 1.1 M (-6.20 %) |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Sell | S | 70.94 | 70,000 | 4,965,590 | 1,058,963 | 1.1 M to 1.1 M (-6.20 %) |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Buy | M | 20.74 | 70,000 | 1,451,800 | 1,128,963 | 1.1 M to 1.1 M (+6.61 %) |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Buy | M | 20.74 | 70,000 | 1,451,800 | 1,128,963 | 1.1 M to 1.1 M (+6.61 %) |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and CEO | Buy | M | 20.74 | 70,000 | 1,451,800 | 1,128,963 | 1.1 M to 1.1 M (+6.61 %) |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 400,000 | |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 400,000 | |
| Aug 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Executive Chairman | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 400,000 |